<DOC>
	<DOCNO>NCT01459419</DOCNO>
	<brief_summary>The use oral aCD3 Monoclonal antibody ( MAb ) alone subject hepatitis C justify basis scientific medical reason . There data multiple animal model aCD3-alone confers efficacy model inflammatory autoimmune disease induces regulatory T cell immune-modulation desire clinical study . These observation reinforce data Phase 1 clinical study show aCD3-alone induced desire immune-modulation term immunological marker regulatory T cell appropriate rise decline certain cytokine level .</brief_summary>
	<brief_title>Oral Administration Anti-CD3 Monoclonal Antibody Non-responder Genotype-I Chronic Hepatitis C Subjects</brief_title>
	<detailed_description>Oral aCD3 MAb administer dosage level 0.2 1.0 5.0 mg per day 30 day . Up 9 subject treat dosage level , 9 subject receive placebo buffer normal saline use diluent MAb . One 20mg tablet Omeprazole ( proton pump inhibitor ) take orally part study drug cocktail order neutralize stomach pH enhance stability MAb . During treatment period , subject ingest study drug/s every day 30 day , follow clinical laboratory effect . Subjects follow Day 60 ( 30 day termination treatment )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Subjects complete informed consent process culminate write informed consent subject . Men woman age 18 65 year ( inclusive ) . Diagnosis chronic active HCV infection base liver biopsy ( within 3 year initiation study ) , Patients fail treatment Interferon PegInterferon Ribavirin ( &lt; 2log change HCV level 12 week treatment ) HCV RNA blood Screening Visit , ≥600 copies/mL Abstinence alternative medication vitaminDcontaining supplement three month prior initiation therapy stipulate . Compensated liver disease follow maximum hematologic , biochemical serologic criterion Screening visit ( WNL=within normal limit ) Hemoglobin ≥ 12 g/dl woman ≥ 13 g/dl men , WBC &gt; 3000/mm3 , Platelets &gt; 100,000/mm3 , Direct bilirubin WNL . Indirect bilirubin WNL , Albumin WNL , Serum Creatinine WNL . ChildPugh score ≤ 6 . Fasting glucose 70 140 mg/dl , result 116140 require HbA1c &lt; 7.5 % Antinuclear antibody ( ANA ) +1 HCV Genotype I patient Subjects undergone surgery within last 3 month . Subjects prior gastrointestinal surgery . Subjects organ transplant cornea hair transplant . Subjects Inflammatory Bowel Disease , malabsorption , symptom diarrhea . Subjects clinically significant ( last 3 month ) infectious , immunemediated malignant disease . Subjects receive elemental diet parenteral nutrition . Subjects treat type immune modulatory drug include systemic steroid NSAID within last 4 week . Subjects receive either methotrexate cyclosporine antiTNF ( infliximab , Remicade ) antiintegrin ( namixilab ) time participate clinical trial within last 3 month . Subjects history coagulopathy . ALT level 10 time normal limit . Women childbearing potential unless use adequate contraception ( either IUD , oral Depoprovera contraceptive , barrier plus spermicide ) ; pregnant breastfeeding mother . Subjects unavailable duration trial , unlikely compliant protocol , felt unsuitable Investigator reason . Subjects HIVpositive . Subjects positive antiHBcAg Subjects active CMV infection . Subjects autoimmune hepatitis Subjects IgG anticardiolipin antibody &gt; 16 IU . Any prior exposure antiCD3 MAb . Known sensitivity ingredient study drug Any know autoimmune disease except studied disorder Subjects excess alcohol use ( &gt; 30 g/day ) Subjects drug addiction base physician 's judgment Subjects TSH &gt; 6 mIU/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>